1. Introduction {#s0005}
===============

Protein glycosylation, which in eukaryotes occurs predominantly in endoplasmic reticulum (ER) and the Golgi apparatus, is the most prevalent and complex post-translational modification. It was originally believed that only eukaryotic membrane-bound or secreted proteins were glycosylated, however it is now known that this process occurs in a range of eukaryotic nuclear and cytoplasmic proteins, as well as in bacteria and archaea. The process of glycosylation covalently attaches a glycan, a reaction catalysed by glycosyltransferases, to the growing end of a carbohydrate chain on a nascent protein or lipid. These complex modifications modulate the properties of the proteins they decorate. These modifications play a crucial role in every aspect of biology including increasing protein solubility [@bb0005]; increasing structural stability and protection from proteolysis [@bb0010]; assistance in protein folding [@bb0005]; participation in immune responses [@bb0015]; cell--cell and cell-extra cellular matrix (ECM) recognition [@bb0020]; and selective protein targeting in both intra- or extracellular destinations [@bb0025]. Glycosylation permits diversity of the proteome by encompassing a wide range of variables such as glycosidic linkages (anomeric configuration; carbon/carbon linkage between sugars, *N*- or *O*-linked), composition, structure and length. In eukaryotes, before any of these glycosylation reactions can occur, the activated sugar must be transported into the Golgi or ER lumen where it can be used as a substrate by glycosyltransferases, a task performed by a family of transport proteins called nucleotide sugar transporters (NSTs).

Cellular membranes, including those that enclose organelles, are biological barriers that selectively either allow, inhibit, restrict or dictate the rate of flow of a range of solutes such as charged organic or inorganic molecules. Transporter proteins are an effective solution to the movement of selected solutes across these hydrophobic barriers that would otherwise be excluded. The second largest family of membrane proteins is the solute carriers (SLC). The SLCs, which is a classification of human transporters, now include 52 families [@bb0030]. With such a range of SLC families, there are a wide variety of solutes that can be transported, from amino acids to sugars, to complex organic molecules. As such, SLCs also contain different transport strategies and mechanisms to achieve their function, such as operating as antiporters, symporters or simple carriers [@bb0035]. The solute carrier family SLC35 (HUGO Gene Nomenclature Committee) comprises members of the evolutionary conserved family of human NSTs. The solute carrier family SLC35 of human NSTs is divided into 7 subfamilies (SLC35A-G), identified on the basis of sequence similarity (SLC35E-G are orphan transporters, that is, their physiological functions are yet to be determined). Each NST subfamily is then divided further to differentiate the type of substrate(s) that is/are transported ([Table 1](#t0005){ref-type="table"}).

2. General features of the nucleotide sugar transporter family {#s0010}
==============================================================

NSTs are highly conserved type III trans-membrane (TM) proteins that provide a link between the synthesis of nucleotide sugars (in the ER, nucleus or cytosol), and the glycosylation process that occurs in the Golgi or ER lumen. It is well-established that NSTs function as antiporters, exchanging cytosolic nucleotide sugar for the corresponding lumenal nucleotide monophosphate ([Fig. 1](#f0005){ref-type="fig"}) [@bb0040; @bb0045; @bb0050; @bb0055; @bb0060]. That is, a constant level of nucleotide sugar is maintained in the Golgi or ER lumen through the equimolar exchange of nucleotide sugar with nucleotide monophosphate. The NST antiporter mechanism has been investigated in NSTs reconstituted into proteoliposomes [@bb0060], yeast Golgi vesicles [@bb0065], and directly in Golgi fractions isolated from rat liver [@bb0050]. Studies using CST reconstituted into phosphatidylcholine proteoliposomes preloaded with CMP significantly stimulated the uptake of CMP-sialic acid in a phenomenon known as *trans*-stimulation [@bb0060]. However, the ability of the CST (and other NSTs) to translocate its corresponding nucleotide sugar in the presence and absence of the antiporter molecular (nucleotide monophosphate) has lead to the characterisation of this transport system as "leaky" [@bb0045; @bb0065; @bb0070].

Thirty years of NST research aimed at identification and biochemical characterisation has identified a number of features that are common to all currently known NSTs (reviewed in [@bb0070]), including:•Translocation of the entire nucleotide sugar;•Translocation is saturable; temperature, concentration and time dependent with apparent *K~m~* in the order of 1--10 μM; and is able to concentrate the nucleotide sugar within the lumen of the ER or Golgi;•Translocation is insensitive to the presence of ATP and ionophores and are energised by the coupled translocation of the corresponding nucleoside monophosphate in the opposite direction (antiporter);•Translocation is competitively inhibited by the corresponding nucleoside mono- and diphosphate, but not by the free sugar;•Some nucleotide sugars are translocated exclusively into the Golgi apparatus, some exclusively in the ER, while others are translocated in both, including some being splice variant dependent.

The initial identification of a range of NSTs was achieved through complementation analysis [@bb0155; @bb0195; @bb0200; @bb0205; @bb0210]. Subsequent characterisation of the majority of these NSTs was with respect to their ability to translocate a single nucleotide sugar [@bb0215; @bb0220], and it was commonly accepted that NSTs had absolute substrate specificities. More recently however, multi-substrate transporters of nucleotide sugars have been described in vitro ([Table 1](#t0005){ref-type="table"}). In *Caenorhabditis elegans* for example, there are 18 putative NSTs, three of which have been well characterised. All three of these have been shown to have multi-substrate specificity including that encoded by the gene ZK896.9, which is capable of transporting UDP-glucose (UDP-Glc), UDP-galactose (UDP-Gal), UDP-*N*-acetylglucosamine (UDP-GlcNAc) and UDP-*N*-acetylgalactosamine (UDP-GalNAc) [@bb0225]. Multi-substrate specificity may be partially explained by a common evolutionary ancestor [@bb0190], or alternatively recent studies have proposed that NST redundancy may be an evolutionary backup mechanism in case of NST impairment, deletion or mutation [@bb0075].

Although the amino acid sequence of a number of NSTs from a range of species has been determined, this information however has not proven to be a good indicator of substrate specificity. For example, the mammalian CMP-sialic acid transporter (CST) and UDP-Gal transporter (UGT) are 43% identical, yet are only able to transport the corresponding nucleotide sugars (CMP-Neu5Ac and UDP-Gal, respectively) [@bb0530], whereas the UDP-GlcNAc transporter (NGT) from *Kluyveromyces lactis*, which shares only 22% identity with the human NGT, has the same nucleotide sugar substrate [@bb0235]. Similarly, in vitro studies show that the transport of UDP-GlcNAc in humans is maintained by 3 different NSTs (SLC35A3, SLC35B4 and SLC35D2) from 3 subfamilies that share very low amino acid identity (see [Table 1](#t0005){ref-type="table"} and references therein).

Little is known regarding the exact structure of NSTs due to the difficulty associated with crystallising membrane proteins. To date, no three-dimensional structure of any NST has been elucidated. What is known is based on computer predictions, mutagenesis experiments, epitope-tagging studies and evolutionary analysis [@bb0070; @bb0240; @bb0245]. In general, NST membrane topology has been predicted to comprise between six to ten trans-membrane (TM) domains linked by hydrophilic loops on both sides of the Golgi membrane [@bb0215; @bb0220; @bb0250]. All NST topologies predicted to date suggest that the C- and N-termini are present on the cytosolic side [@bb0255; @bb0260; @bb0265], corresponding to an even number of TM domains. A distinct exception to this classical NST topology is the *Aspergillus fumigatus* UDP-galactofuranose transporter which has 11 predicted TM domains [@bb0270]. It has been shown that several Golgi apparatus NSTs such as those that transport UDP-GalNAc, GDP-Fuc, ATP and PAPS appear as homodimers [@bb0040], whereas the GDP-Man transporter (GMT) from *Leishmania donovani* is presumed to be a hexamer in solution [@bb0275]. As well as potential homo-oligomers being formed in the membrane, there are also reports describing interactions, or possible complexes being formed between NSTs and glycosyltransferases [@bb0280]. Sprong et al. also concluded that the ceramide galactosyltransferase guarantees an adequate supply of UDP-Gal in the ER lumen by retaining the UGT in a molecular complex [@bb0285].

Thus far the oligomeric state of a functional NST has not been conclusively determined. For readers interested in inverted membrane protein topologies and conformational dynamics of antiporters we recommend the following reviews [@bb0535; @bb0295].

3. SLC35A2: UDP-galactose (UGT) and SLC35A3: UDP-*N*-acetylglucosamine (NGT) transporters {#s0015}
=========================================================================================

The cDNA that encodes for the human UDP-Gal transporter (UGT) was first cloned and characterised by Muira et al., in 1996 [@bb0210], and was believed to have been the first mammalian NST cDNA sequence described. Detailed characterisation of the UGT was possible using the mutant cell lines MDCK-RCA^r^ [@bb0300; @bb0305], CHO-Lec8 [@bb0310; @bb0315] and Had-1 [@bb0255]. Complementation of these UGT defective cell lines restored transport activity, and expression of recombinant UGT in mammalian and yeast cells confirmed its localisation and specificity [@bb0205; @bb0210; @bb0320; @bb0325]. Interestingly, two isoforms of gene encoding the UGT, *UGT1* and *UGT2* have been identified in humans [@bb0205; @bb0210]. Analyses of these human splice variants show that the only difference is confined to the proteins extreme C-termini. UGT1 is localised only in the Golgi apparatus, whereas the UGT2 C-terminus contains a dilysine motif that is responsible for dual localisation in the Golgi and ER [@bb0330]. A recent study concluded that although UGT2 is more abundant in nearly all mammalian tissues and cell lines tested, expression of both splice variants is important for glycosylation of proteins in mammalian cells [@bb0335].

Compared to several other well-characterised transporters, the UDP-GlcNAc transporter (NGT) shows limited amino acid sequence identity to other NGTs that transport the same substrate, in particular yeast and mammals [@bb0210]. It has been proposed that the transport mechanisms of the UGT and NGT may be coupled. The overexpression of NGT in MDCK-RCA^r^ (Madin-Darby canine kidney-ricin resistant) and CHO-Lec8 mutant cells defective in UGT has been found to restore galactosylation of N-glycans [@bb0340]. These cells lack UDP-Gal transport in the Golgi apparatus and therefore are unable to add Gal to glycans [@bb0345]. Although NGT overexpression restored UDP-Gal transport, it also resulted in the decrease of transport of its natural substrate UDP-GlcNAc into the Golgi. This data suggested that the biological function of both the NGT and UGT in galactosylation might be coupled. Recent investigations into substrate specificity of the UGT have shown that the UGT/CST can function as a chimeric transporter [@bb0350], this is addressed in more detail later in this review.

Using co-immunoprecipitation analysis and FLIM-FRET measurements on living cells, it was demonstrated that NGT and UGT form complexes when overexpressed in MDCK-RCA^r^ cells [@bb0355]. This suggested that NGT/UGT complexes either mediate transport of both substrates (UDP-Gal and UDP-GlcNAc) or alternatively these complexes just bring the NGT and UGT homodimers together. Either way, the ability of NGT and UGT to interact with each other may be a regulation mechanism of N-glycan biosynthesis in the Golgi by ensuring adequate supply of both natural substrates to their respective glycosyltransferases. It was concluded that the NGT and UGT function in glycosylation is combined via their mutual interaction [@bb0355; @bb0360]. However, it must be stressed that these studies are based on overexpression of the NGT and UGT, and therefore may not truly reflect the physiological situation. Interestingly, overexpression of certain receptors [@bb0365; @bb0370; @bb0375] has been shown to create a "Brefeldin effect" [@bb0380]. Brefeldin A (BFA) is a fungal metabolite that affects the molecular mechanisms regulating membrane traffic and organelle structure [@bb0375]. Treatment with BFA leads to a rapid accumulation of proteins in the ER and a collapse of the Golgi stacks [@bb0385]. The result is that the Golgi apparatus largely disappears leaving Golgi proteins to intermix with those in the ER. With overexpression of these particular proteins, the effects were phenotypically indistinguishable from those treated with the addition of BFA.

More recently a number of CDGs have been identified due to SLC35A2 (UGT) and SLC35A3 (NGT) mutation [@bb0095; @bb0100; @bb0115], specifically SLC35A2 has been implicated in early-onset epileptic encephalopathy and SLC35A3 in autism.

4. SLC35C1: GDP-fucose transporter (GFT) {#s0020}
========================================

The GDP-fucose transporter (GFT) regulates the fucosylation of glycans predominantly in the Golgi. It was first identified using complementation cloning during investigations into the Congenital Disease of Glycosylation-IIc (CDGIIc), now known as Leukocyte Adhesion Deficiency II (LADII). This disease is characterised by a lack of fucosylated glycoconjugates [@bb0150; @bb0155] resulting in immunodeficiency and severe mental and growth retardation [@bb0390]. It was purported that a deficient GFT was responsible for this disease state [@bb0150; @bb0155]. Interestingly, the GFT shows a substantial level of amino acid conservation with both the CST and UGT [@bb0150; @bb0155] however, even now, the elements essential for activity and localisation of the GFT remain poorly understood [@bb0395]. Although overexpression of SLC35C2 (a putative GFT) also shows slight competition with the GFT in the O-fucosylation of Notch, GFT is essential for the core fucosylation of N-glycans [@bb0395] and optimal Notch signalling in mammalian cells [@bb0165].

As with all NSTs, elucidating the structure--function relationship remains elusive due to the lack of a crystal structure. Studying the GFT has had an added challenge due to the lack of an appropriate mutant cell line. Recently, a novel Chinese hamster ovary (CHO) mutant (CHO-gmt5) was established that harboured double genetic defects in both the CST and GFT producing N-glycans deficient in both sialic acid (Sia) and fucose (Fuc) [@bb0395]. Studies using this mutant found that the C-terminal tail of the GFT was critical for its activity (Fuc-binding lectin recognition) but not localisation to the Golgi, in contrast to the murine CST [@bb0400] and several other transporters. This latest CHO-gmt5 study highlights several new structure/function relationships for this transporter [@bb0395].

5. SLC35D2: UDP-*N*-acetylglucosamine/UDP-glucose transporter (HFRC1) also known as GDP-mannose transporter in non-humans (GMT) {#s0025}
===============================================================================================================================

The GDP-mannose transporter (GMT) from *L. donovani* and *Saccharomyces cerevisiae* was originally identified and characterised in 1997 [@bb0540; @bb0410]. In 2003 a novel human nucleotide sugar transporter gene, *hfrc1*, was cloned and characterised as being a multi-substrate specific NST homologous to *Drosophila melanogaster fringe connection*, *C. elegans sqv*-*7* and human *UGTrel7*. In yeast, the heterologous expression of HFRC1 revealed the multi-substrate transport of UDP-GlcNAc, UDP-Glc and GDP-Man. Interestingly, and importantly, when expressed in mammalian cells, UDP-GlcNAc and UDP-Glc were transported but GDP-Man was not [@bb0415]. HFRC1 was subsequently identified and characterised as a member of SLC35D2 by the same group that had previously identified and characterised the murine and human SLC35D1 [@bb0420; @bb0425]. The transporter encoded by *hfrc1* is localised in the Golgi apparatus and exhibits approximately 50% identity with the human SLC35D1 [@bb0420]. It should be stressed that confirming GMT function in yeast is problematic as yeast possesses a high level of endogenous GDP-Man transport that can potentially interfere with the detection of heterologous expressed GMT activity [@bb0430].

The GMT is fundamentally essential for pathogens such as *A. fumigatus* whose cell wall is comprised predominantly of galactomannan, the main defence against the host immune system [@bb0435]. The key role played by the GMT in the biosynthesis of the fungal galactomannan cell wall was recently highlighted by the absence of galactomannan synthesis following the targeted deletion of the GMT [@bb0440]. This suggests that the GMT may be an attractive target for drug discovery, particularly given the lack of a human GMT activity [@bb0415]. Similarly, the protozoa Leishmania is protected by a glycocalyx composed mainly of Gal- and Man-glycoconjugates. This protective coat is a virulence factor that shields the parasite from hostile environments and supports its development and method of invasion. As with the cell wall of *A. fumigatus*, interruption of the corresponding essential transporter GMT in *L. donovani* had a severe impact on its pathogenicity [@bb0445].

We have recently utilised a Saturation Transfer Difference NMR spectroscopy (STD NMR) [@bb0450; @bb0455] approach to complement functional used assays to monitor the interaction of nucleotides and nucleotide sugars with the NSTs present in isolated Golgi-enriched fractions [@bb0460; @bb0465; @bb0475]. STD NMR is based on saturating the protein resonances with a cascade of selective pulses (*on*-resonance spectrum). The magnetization is rapidly transferred through the entire protein mediated by spin diffusion. If a ligand is in fast exchange with the protein-binding site then the saturation can be transferred to the binding ligand. Ligand protons that are in closest contact with the protein will receive a higher degree of saturation than ligand protons that are more solvent exposed. A spectrum without any saturation (*off*-resonance spectrum) is simultaneously acquired and subtraction of the *on*-resonance spectrum and the *off*-resonance spectrum results in the final difference spectrum (STD) showing only signals from binding ligands. Additionally, protons in close proximity to the protein surface will show stronger STD NMR signals compared to ligand protons that are solvent exposed. Non-binding ligands will not show any STD NMR signals at all [@bb0550].

Utilising our STD NMR spectroscopy approach we directly investigated the binding of GDP-Man, GDP, GMP and Man to the Golgi-enriched fractions isolated from Aspergillus ([@bb0465] and [Fig. 2](#f0010){ref-type="fig"}). We showed through STD NMR competition experiments that GDP binds tighter to the Aspergillus GMT than GMP and GDP-Man, with Man binding only weakly. Based on these experiments the relative importance/affinity of individual ligand moieties that bind the Aspergillus GMT were summarised as follows; GDP ≥ GMP ≃ GDP-Man ≫ Man. The natural antiporter substrates for the GMT are GDP-Man and GMP. However, the observation that GDP binds the GMT with higher affinity than the natural substrates (GMP-Man and GMP) can now be exploited in the design of novel GMT inhibitors [@bb0465]. (See [Fig. 2](#f0010){ref-type="fig"}.)

6. SLC35A1 CMP-sialic acid transporter (CST) {#s0030}
============================================

The CST is located exclusively in the Golgi apparatus where it co-localises with ST6GalI in the medial and trans Golgi, and translocates CMP-sialic acid (CMP-Sia) from the cytosol into the Golgi lumen in exchange for CMP in an antiporter mechanism (see [Fig. 1](#f0005){ref-type="fig"}) [@bb0070]. The cDNA of the murine CST was first isolated in 1996 by complementation cloning. Chinese hamster ovary mutants of the complementation group Lec2 (CHO 6B2) express a strong reduction of sialylated glycoconjugates due to a defect in the CST. By expression cloning, a cDNA encoding the mCST was identified that complemented the Lec2 phenotype [@bb0485]. It was shown to encode a highly hydrophobic, multiple membrane spanning protein of 36.4 kDa. Using the same cloning strategy the cDNA encoding the hamster CST was also isolated with the amino acid sequence showing a 95% identity with the mCST [@bb0490]. Related cDNAs from human, *S. cerevisiae*, and *C. elegans* were also identified by homology searches of gene databases. Expression of the murine CST in yeast was used to confirm the ability of the cloned CST to translocate CMP-Sia [@bb0065]. Due to the fact that yeast does not express Sia, it represented an ideal background free model to study the CST and to demonstrate that the cDNA identified by complementation cloning encoded an active transporter and not just an accessory protein required for CMP-Sia transport/translocation.

Subsequent to cloning and expression of the CST, independent groups began structure--function relationship investigations. Initially, the CST derived from five independent clones of the Lec2 complementation group were analysed to determine the molecular defects leading to the inactivation of the CST. One of these defects was observed to be a single missense mutation, Gly189Glu. It was shown that the mutant CST mRNA expression level was the same as that of the wild-type, and the mutant was also correctly targeted to the Golgi apparatus. This indicated that the Gly189Glu mutation was directly responsible for the inactivation of CST transport activity. Exchanging Gly189 to Ala did not affect transport, though Gly189Gln and Gly189Ile mutants resembled the inactivate Gly189Glu mutant ([Table 2](#t0010){ref-type="table"} and Supplementary data [Table A](#ec0010){ref-type="supplementary-material"}). This suggested that the insertion of a large amino acid at this position 189 rather than the charge associated with Glu that rendered the CST inactive. The exchange Gly189 to Glu occurs in a region that is highly conserved in both the mammalian CST and UGT, as well as in *Schizosaccharomyces pombe* and *C. elegans*, suggesting this region is essential for a functional transporter [@bb0495].

Subsequent to cloning and expression of the CST, independent groups began structure--function relationship investigations. Initially, the CST derived from five independent clones of the Lec2 complementation group were analysed to determine the molecular defects leading to the inactivation of the CST. One of these defects was observed to be a single missense mutation, Gly189Glu. It was shown that the mutant CST mRNA expression level was the same as that of the wild-type, and the mutant was also correctly targeted to the Golgi apparatus. This indicated that the Gly189Glu mutation was directly responsible for the inactivation of CST transport activity. Exchanging Gly189 to Ala did not affect transport, though Gly189Gln and Gly189Ile mutants resembled the inactivate Gly189Glu mutant ([Table 2](#t0010){ref-type="table"} and Supplementary data Table A). This suggested that the insertion of a large amino acid at position 189 rather than the charge associated with Glu rendered the CST inactive. The exchange Gly189 to Glu occurs in a region that is highly conserved in both the mammalian CST and UGT, as well as in *Schizosaccharomyces pombe* and *C. elegans*, suggesting this region is essential for a functional transporter [@bb0495].

The initial topology model established by Eckhardt et al. (1999) predicted 10 TM domains with both the N- and C-terminals facing the cytosolic side of the Golgi membrane ([Fig. 3](#f0015){ref-type="fig"}). This model was deduced by epitope-tagging studies, site-directed mutagenesis and hydrophobicity plots [@bb0260], and established that Gly189 is one of 10 Gly residues spread across four TM domains (TM 5--8) that were presumed to form a putative hydrophilic channel [@bb0495]. The creation of eight double mutants exchanging each Gly pair with Ala and Ile confirmed the importance of these Gly residues [@bb0500] ([Fig. 3](#f0015){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}). In order to assess these and other mutants Lim et al. (2008) established the EPO/IEF assay to assess CST activity. Briefly, recombinant human erythropoietin (EPO) is a heavily glycosylated molecule and a simple analysis of the sialylation pattern using isoelectric focusing (IEF) can identify any changes in these patterns. MAR-11 CHO cells lack a functional CST and these cells were used as the host to analyse the relative activities of different mutant transporters. Using this assay system Lim et al. (2008) concluded that there was a direct correlation between the increased steric hindrance associated with the exchange of Gly with either Ala or Ile and the reduction of CST substrate translocation [@bb0500].

The suggestion of a Gly-rich hydrophilic channel or pore through which CMP-Sia can pass is contradictory to the hypothesis that the CST is a simple solute carrier [@bb0060] and to the concept of an antiporter mechanism [@bb0220]. This was based on experimental evidence that the transporter has the ability to alternatively expose its CMP/CMP-Sia binding site from either the cytosolic or luminal side of the Golgi membrane [@bb0060]. However, the two hypotheses can be reconciled in that the binding of CMP or CMP-Sia to the CST may permit a conformational change that allows the formation of a Gly-rich hydrophilic channel, enabling the selective translocation of the bound molecule. This unfortunately can only be conclusively demonstrated through the elucidation of the CST crystal structure.

Much of what we know regarding the CST (and UGT) structure--function relationship comes from a series of elegant studies evaluating the function of an array of UGT/CST chimeric transporters in both Lec2 and Lec8 CHO complementation groups [@bb0530; @bb0350; @bb0505]. Initial studies showed that substitution of CST helix 7 into the UGT chimera was enough to elicit CST activity, with the addition of helices 2 and/or 3 greatly enhancing the efficiency, suggesting that this chimeric CST/UGT now had the ability to recognise and transport both UDP-Gal and CMP-Sia [@bb0530; @bb0505] ([Table 2](#t0010){ref-type="table"}). More recently further analysis of UGT/CST chimeras has defined a sub-molecular region that is necessary for CMP-Sia recognition [@bb0350]. Analysis of chimeras indicated that the Val208--Gly217 stretch in the CST (located in the helix 7) was essential for CST activity. Two of the amino acids located in this stretch, Tyr214 and Ser216 were subsequently identified by site-directed mutagenesis (both single and double mutants) to be important for CMP-Sia recognition, with Tyr214 found to be critical for substrate recognition ([Table 2](#t0010){ref-type="table"}). The authors postulated that hydrogen bond formation involving the hydroxyl side-chains of these two amino acids may make specific interaction with the Sia moiety of the substrate [@bb0350].

Utilising STD NMR spectroscopy we were able to confirm the importance of Tyr214 in CMP-Sia recognition, specifically that it is intimately involved in the recognition and binding to the Sia moiety of CMP-Sia [@bb0475]. The generation of a Tyr214Ala CST mutant leads to the complete loss of STD signals associated with Sia, even though significant binding was observed to the CMP moiety. In addition to Tyr214, we were also able to identify another CST mutant, Lys65Ala that leads to a significant reduction in CMP-Sia recognition [@bb0475]. The latter residue in particular was identified using a bio-informatic approach where a sequence alignment of the mouse and human UGT and seven evolutionary diverse CSTs (*H. sapiens*, *Mucaca mulatta*, *Mus musculus*, *Gallus gallus*, *Xenopus laevis*, *Takifugu rubripes*, and *Danio rerio*) was performed. As shown in [Supplementary Fig. A](#ec0005){ref-type="supplementary-material"}, a number of structural elements including the 10 Gly residues stretching TM 5--8 that have been implicated in the formation of a transporter channel [@bb0500], and Gln101, Leu136, and Lys272 and residues in the human CST loop regions shown to be essential for transport activity [@bb0510] appear not to confer substrate specificity as they are conserved in both the CST and UGT. However, Ser216 and Tyr214, independently identified by Maggioni et al. [@bb0475] and Takeshima-Futagami et al. [@bb0350] as being important for CMP-Sia recognition are highly conserved in evolutionary distant CST, but are not found in either the mouse or human UGT. [Supplementary Fig. A](#ec0005){ref-type="supplementary-material"} also reveals the presence of seven Cys residues absolutely conserved in all CSTs that are not present in the UGT. Three Cys residues are present within the UGT, but their locations differ to those present in the CST sequence. To further explore the role of these Cys residues in disulphide bond formation, a web-based disulphide bond prediction algorithm DiANNA [@bb0515] was used to analyse the CST and UGT sequence. Of the seven Cys residues in the CST six were predicted to form disulphide bonds, giving both intra- and inter-TMD connections. The Cys putatively involved in disulphide bond formation are Cys16--Cys49 (TMD1--TMD2), Cys127--Cys131 (TMD4--TMD4) and Cys152--Cys307 (TM5--TM9) (highlighted in Fig. A2). Of the three Cys residues in the UGT none were predicted to be involved in disulphide bond formation [@bb0475]. We therefore explored how the disruption of two of these putative disulphide bonds in the CST (C16A and C152A, [Supplementary Fig. A](#ec0005){ref-type="supplementary-material"}) affected CST substrate recognition. However only Cys16Ala had any effect on CMP-Sia binding as assessed by STD NMR spectroscopy, this is despite the fact that alkylating and reducing agents completely abolished CST--CMP-Sia interaction [@bb0475]. This is interesting in so far as sialyltransferases contain two to four invariant Cys residues that are all involved in CMP-Neu5Ac substrate binding. These Cys residues are indispensable to the structural and functional integrity of sialyltransferases, with complete loss of catalytic activity observed following the mutation of either invariant Cys to Ala or Ser [@bb0520]. However, unlike sialyltransferases where the mutation of single Cys residues abolishes activity, it would appear that in the CST disruption of multiple Cys is required to achieve a similar outcome.

Utilising STD NMR spectroscopy we were able to confirm the importance of Tyr214 in CMP-Sia recognition, specifically that it is intimately involved in the recognition and binding to the Sia moiety of CMP-Sia [@bb0475]. The generation of a Tyr214Ala CST mutant leads to the complete loss of STD signals associated with Sia, even though significant binding was observed to the CMP moiety. In addition to Tyr214, we were also able to identify another CST mutant, Lys65Ala that leads to a significant reduction in CMP-Sia recognition [@bb0475]. The latter residue in particular was identified using a bio-informatic approach where a sequence alignment of the mouse and human UGT and seven evolutionary diverse CSTs (*H. sapiens*, *Mucaca mulatta*, *Mus musculus*, *Gallus gallus*, *Xenopus laevis*, *Takifugu rubripes*, and *Danio rerio*) was performed. As shown in Supplementary Fig. A, a number of structural elements including the 10 Gly residues stretching TM 5--8 that have been implicated in the formation of a transporter channel [@bb0500], and Gln101, Leu136, and Lys272 and residues in the human CST loop regions shown to be essential for transport activity [@bb0510] appear not to confer substrate specificity as they are conserved in both the CST and UGT. However, Ser216 and Tyr214, independently identified by Maggioni et al. [@bb0475] and Takeshima-Futagami et al. [@bb0350] as being important for CMP-Sia recognition are highly conserved in evolutionary distant CST, but are not found in either the mouse or human UGT. Supplementary Fig. A also reveals the presence of seven Cys residues absolutely conserved in all CSTs that are not present in the UGT. Three Cys residues are present within the UGT, but their locations differ to those present in the CST sequence. To further explore the role of these Cys residues in disulphide bond formation, a web-based disulphide bond prediction algorithm DiANNA [@bb0515] was used to analyse the CST and UGT sequence. Of the seven Cys residues in the CST six were predicted to form disulphide bonds, giving both intra- and inter-TMD connections. The Cys putatively involved in disulphide bond formation are Cys16--Cys49 (TMD1--TMD2), Cys127--Cys131 (TMD4--TMD4) and Cys152--Cys307 (TM5--TM9) (highlighted in Fig. A2). Of the three Cys residues in the UGT none were predicted to be involved in disulphide bond formation [@bb0475]. We therefore explored how the disruption of two of these putative disulphide bonds in the CST (C16A and C152A, Supplementary Fig. A) affected CST substrate recognition. However only Cys16Ala had any effect on CMP-Sia binding as assessed by STD NMR spectroscopy, this is despite the fact that alkylating and reducing agents completely abolished CST--CMP-Sia interaction [@bb0475]. This is interesting in so far as sialyltransferases contain two to four invariant Cys residues that are all involved in CMP-Neu5Ac substrate binding. These Cys residues are indispensable to the structural and functional integrity of sialyltransferases, with complete loss of catalytic activity observed following the mutation of either invariant Cys to Ala or Ser [@bb0520]. However, unlike sialyltransferases where the mutation of single Cys residues abolishes activity, it would appear that in the CST disruption of multiple Cys is required to achieve a similar outcome.

In addition to the importance of specific TM domains in CST and UGT activities, the function of the CST hydrophilic loops through green fluorescent protein (GFP) insertion experiments has also been assessed [@bb0510]. Three distinct loops that congregate around TMD3 and TMD7, as well as several highly conserved amino acids were found to be crucial for the transport activity of both the CST and UGT ([Table 2](#t0010){ref-type="table"} and highlighted in orange in [Fig. 3](#f0015){ref-type="fig"}).

7. Summary and outlook {#s0035}
======================

Significant progress has been made over the past decade towards not only the elucidation of NST structure--function relationship, but also better understanding the role of NSTs in various disease states including CDGs and microbial pathogenesis (e.g. *A. fumigatus* and Leishmania). These data have been generated using a multidisciplinary approach employing techniques ranging from site directed mutagenesis and complementation analyses to STD NMR spectroscopy and transport assays. The studies covered in this review have provided a fundamental understanding of several important NSTs. The continued use of multidisciplinary approaches towards understanding NST structure and function will provide further important advances in the field. However, only with the elucidation of the 3-dimensional structure of an NST will a full understanding of the structure--function relationship of this important class of transporter be realised.

The following are the supplementary data related to this article.Supplementary Fig. AMultiple protein sequence alignment of seven CSTs and two UGTs. Cys residues predicted to form disulphide bonds between TMD1--TMD2 (↓), TMD4--TMD4 (†) and TMD5--TMD9 (\#) are indicated. Putative trans-membrane domains (TM) are underlined and labelled TM1--TM9. TM 2, 3 and 7 are shaded grey, residues known to be involved in transport activity are boxed in black, and residues conserved in all studied CSTs boxed in red.Supplementary Table ACST and CST/UGT chimeric mutations.

Supplementary data to this article can be found online at [http://dx.doi.org/10.1016/j.csbj.2014.05.003](10.1016/j.csbj.2014.05.003){#ir0055}.

![The general transport mechanism of NSTs. The XDP-sugar (nucleotide sugar donor) enters the lumen of the organelle in exchange for the corresponding nucleoside monophosphate (XMP). After entering the lumen the sugar is transferred to either a protein or lipid in a reaction catalysed by glycosyltransferases. The diphosphate nucleotide (XDP) is then acted upon by a membrane-bound nucleotide diphosphatase [@bb0185] producing the XMP that is subsequently exported [@bb0190]. In some cases where the nucleotide sugar donor is a monophosphate, the dephosphorylation reaction performed by the diphosphatase is not required.](gr1){#f0005}

![The direct analysis of Aspergillus GMT interaction with GDP-Man, GDP and GMP using STD NMR spectroscopy. ^1^H (a) and competition STD NMR spectra of Aspergillus Golgi-enriched fractions complexed with GDP-Man (b) followed by the addition of equimolar amounts of GMP (c) and GDP (d). Some STD signals were found to increase due to overlapping chemical shifts (e.g. the H1 ribose signal at 5.65 ppm), however the H8 guanine signal of the three ligands does not have the same chemical shift and therefore could be used to monitor the interaction of the GMT with GDP-Man, GDP and GMP. The H8 GuaGDP-Man signal (b) is reduced following the addition of GMP and GDP (c and d, respectively) with a corresponding appearance of H8 guanine signals associated with GMP and GDP. Specific mannose signals were reduced by ∼ 50% following the addition of equimolar GMP (c), and the signals after addition of GDP (d) showed a further reduction of ∼ 50% compared to (c).](gr2){#f0010}

![Diagram representing the membrane topology of CST as proposed by independent studies. 1. TM1--TM10 were identified using HA-epitope tagging [@bb0260]. The position of HA epitopes used to deduce this model is indicated by arrows and arrowheads. Black arrows and arrowheads indicate HA tags that inactivated CST, whereas the green arrowheads mark the position of HA tags that did not inactivate the CST. 2. The TM domains coloured in yellow are essential for CST activity as identified through UGT--CST chimeras [@bb0505]. When TM2, TM3 and TM7 from CST were engineered into UGT, the resulting transporter was then able to transport both CMP-Sia and UDP-Gal. 3. Deletion of the four purple coloured amino acids eliminated the export signals and prevented ER to Golgi translocation [@bb0400] 4. The blue coloured Gly residues were identified as contributing to the formation of a putative aqueous channel necessary for the translocation of CMP-Sia [@bb0500]. 5. The orange coloured amino acids ringed in black were identified by GFP-tagging as essential for CST activity. The orange amino acids with no black ring were identified as essential by point mutations [@bb0510]. 6. Amino acids in red were identified as being essential for CST substrate recognition [@bb0475]. Diagram modified from Eckhardt, Gotza & Gerardy-Schahn (1999) [@bb0260] and Maggioni, Martinez-Duncker & Tiralongo (2013) [@bb0070].](gr3){#f0015}

###### 

Selected members of the SLC35 nucleotide sugar transporter family.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SLC nomenclature   NCBI preferred name                       Substrate                                                              Sub-cellular localisation   Link to disease                                                                                                                    Ensembl ID
  ------------------ ----------------------------------------- ---------------------------------------------------------------------- --------------------------- ---------------------------------------------------------------------------------------------------------------------------------- -----------------
  SLC35A1            CMP-Sia transporter (CST)                 CMP-Sia                                                                Exclusively Golgi           Congenital disorder of glycosylation (CDG2F) (OMIM \#[603585](603585){#ir0030}) [@bb0075; @bb0080]                                 ENSG00000164414

  SLC35A2            UDP-Gal transporter (UGT)                 UDP-Gal;\                                                              Golgi and/or ER             Colon cancer [@bb0085]; Wiskott-Aldrich syndrome [@bb0090]\                                                                        ENSG00000102100
                                                               UDP-GlcNAc                                                                                         CDG2M (OMIM \#[300896](300896){#ir0035}) [@bb0095; @bb0100]                                                                        

  SLC35A3            UDP-GlcNAc transporter (NGT)              UDP-GlcNAc                                                             Predominantly Golgi         Possible link to malaria through UDP-GlcNAc transporter homolog [@bb0105]\                                                         ENSG00000117620
                                                                                                                                                                  Musculoskeletal abnormalities in cattle [@bb0110]\                                                                                 
                                                                                                                                                                  Arthrogryposis, mental retardation, and seizures (OMIM \#[615553](615553){#ir0040}) [@bb0115]                                      

  SLC35A4            Probable UDP-sugar transporter; MGC2541   Putative UDP-Gal                                                                                                                                                                                                                      ENSG00000176087

  SLC35A5            Probable UDP-sugar transporter            Putative UDP-sugar                                                                                                                                                                                                                    ENSG00000138459

  SLC35B1            UGTREL1                                   Putative sugar transporter                                                                                                                                                                                                            ENSG00000121073

  SLC35B2            PAPS transporter 1                        PAPS                                                                   Exclusively Golgi           Colorectal cancer [@bb0120]; Dysplasia [@bb0525]                                                                                   ENSG00000157593

  SLC35B3            PAPS transporter 2                        PAPS                                                                   Exclusively Golgi           Overexpression in hepatocarcinoma cell line [@bb0130]; Colon cancer [@bb0135] Dysplasia [@bb0525]                                  ENSG00000124786

  SLC35B4            UDP-Xyl transporter\                      UDP-Xyl;\                                                              Golgi and/or ER             Regulation of obesity & glucose homeostasis in mice [@bb0140]\                                                                     ENSG00000205060
                     (YEA)                                     UDP-GlcNAc                                                                                         PHACE syndrome [@bb0145]                                                                                                           

  SLC35C1            GDP-Fuc transporter (GFT)                 GDP-Fuc                                                                Predominantly Golgi         Leukocyte adhesion deficiency (CDG2C) (OMIM \#[266265](266265){#ir0045}) [@bb0150; @bb0155]; hepatocellular carcinoma [@bb0160].   ENSG00000181830

  SLC35C2            OVCOV1                                    Putative GDP-Fuc transporter. Promotes Notch1 fucosylation [@bb0165]                               Ovarian cancer [@bb0170]                                                                                                           ENSG00000080189

  SLC35D1            UDP-GlcA/UDP-GalNAc dual transporter      UDP-GlcA;\                                                             Exclusively ER              Schneckenbecken dysplasia (OMIM \#[269250](269250){#ir0050}) [@bb0175]                                                             ENSG00000116704
                                                               UDP-GalNAc                                                                                                                                                                                                                            

  SLC35D2            UDP-GlcNAc/UDP-Glc/\                      UDP-GlcNAc;\                                                           Exclusively Golgi                                                                                                                                              ENSG00000130958
                     GDP-Man transporter\                      UDP-Glc;\                                                                                                                                                                                                                             
                     (HFRC1)                                   GDP-Man (not humans)                                                                                                                                                                                                                  

  SLC35D3            FRCL1                                     Substrate unknown                                                                                  Chediak-Higashi syndrome [@bb0180]; Hermansky-Pudlak syndrome [@bb0180].                                                           ENSG00000182747
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

CST and CST/UGT chimeric mutations that altered transport and/or substrate recognition. CST and CST/UGT chimeric mutants shown to affect the transport and/or substrate recognition have been summarised. A complete list of all CST and CST/UGT mutants (based on the available literature) assessed including those that had no effect on transport and/or substrate recognition has been included in the supplementary data Table A.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mutant                                Location          Background                                                                                    Effect                                                                                                         Experiment                                        Comments
  ------------------------------------- ----------------- --------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  C16A                                  TMD 1             Site-directed mutagenesis of mouse CST. Generated and expressed in *P. pastoris*.             Essential for CST substrate specificity                                                                        STD NMR spectroscopy                              Highly conserved in CSTs, but not present in Mn & Hn UGT [@bb0475].

  K65A                                  2nd loop          Site-directed mutagenesis of mouse CST. Generated and expressed in *P. pastoris*.             Significant effect on CMP-Neu5Ac recognition. Suggests binding the Sia moiety and not the nucleotide moiety.   STD NMR spectroscopy                              Highly conserved in CSTs, but not present in Mn & Hn UGT [@bb0475].

  Q101H                                 TMD 3             Naturally occurring mutation in patient with intellectual disability and bleeding diathesis   50% reduction in CST activity                                                                                  Functional assay                                  [@bb0080]

  L112G & D113G\                        3rd loop          CST-GFP12 mutant. Co-transfected with an EPO vector into CHO MAR-11 cells                     Complete inactivation of CST                                                                                   EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0510]
  Double mutant                                                                                                                                                                                                                                                                                                          

  L136G                                 4th loop          MAR-11 cells                                                                                  Essential for CST activity                                                                                     EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   Highly conserved in CST. UGT conserved counterpart, L160G did not affect UGT [@bb0510].

  G153A & G154A\                        TMD 5             Cotransfection of constructs that express CST into CHO CST-deficient MAR-11 cells.            Slightly reduced activity                                                                                      EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0500]
  Double mutant                                                                                                                                                                                                                                                                                                          

  G153I & G154I\                        TMD 5             Cotransfection of constructs that express CST into CHO CST-deficient MAR-11 cells.            Clear reduction in activity                                                                                    EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0500]
  Double mutant                                                                                                                                                                                                                                                                                                          

  G177A & G179A\                        TMD 6             Cotransfection of constructs that express CST into CHO CST-deficient MAR-11 cells.            Slightly reduced activity                                                                                      EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0500]
  Double mutant                                                                                                                                                                                                                                                                                                          

  G177I & G179I\                        TMD 6             Cotransfection of constructs that express CST into CHO CST-deficient MAR-11 cells.            Clear reduction in activity                                                                                    EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0500]
  Double mutant                                                                                                                                                                                                                                                                                                          

  G189A & G192A\                        TMD 6             Cotransfection of constructs that express CST into CHO CST-deficient MAR-11 cells.            Clear reduction in activity                                                                                    EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0500]
  Double mutant                                                                                                                                                                                                                                                                                                          

  G189E                                 TMD 6             Site-directed mutagenesis. Expressed in CHO-WT and mutant Lec 2                               Clear reduction in activity                                                                                    Complementation analysis                          Gly189 in highly conserved CST region. Indicates size of aa is critical for activity --- not charge [@bb0495].

  G189Q                                 TMD 6             Site-directed mutagenesis. Expressed in CHO-WT and mutant Lec 2                               Clear reduction in activity                                                                                    Complementation analysis                          As above [@bb0495].

  G189I                                 TMD 6             Site-directed mutagenesis. Expressed in CHO-WT and mutant Lec 2                               Clear reduction in activity                                                                                    Complementation analysis                          As above [@bb0495].

  Y214A                                 TMD 7             Site-directed mutagenesis of Mouse CST. Generated and expressed in *P. pastoris*.             Dramatic effect on CMP-Neu5Ac recognition. Suggests binding of the Sia moiety and not the nucleotide moiety.   STD NMR spectroscopy                              Highly conserved in CSTs, but not present in Mn & hUGT [@bb0495]

  Y214G                                 TMD 7             hUGT/hCST chimera                                                                             Loss of CST activity (retained UGT activity)                                                                   Complementation analysis                          [@bb0350]

  S216F                                 TMD 7             hUGT/hCST chimera                                                                             Loss of CST activity (retained UGT activity)                                                                   Complementation analysis                          [@bb0350]

  ^236^KGFF^239^ to ^236^GGGG^239^      8th loop          CST-GFP12 mutant. Co-transfected with an EPO vector into CHO MAR-11 cells                     Complete inactivation of CST                                                                                   EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0510]

  G256I & G257I\                        TMD 8             Cotransfection of constructs that express CST into MAR-11 cells.                              Clear reduction in activity                                                                                    EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0500]
  Double mutants                                                                                                                                                                                                                                                                                                         

  G256A & G257A\                        TMD 8             Cotransfection of constructs that express CST into CST-deficient MAR-11 cells.                Clear reduction in activity                                                                                    EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0500]
  Double mutants                                                                                                                                                                                                                                                                                                         

  ^267^TDNI^270^ to ^267^GGGG^270^      8th loop          CST-GFP12 mutant. Co-transfected with an EPO vector into CHO MAR-11 cells                     Complete inactivation of CST                                                                                   EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0510]

  I270G                                 8th loop          CST-GFP12 mutant. Co-transfected with an EPO vector into CHO MAR-11 cells                     Partially reduced transport activity                                                                           EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0510]

  I270W                                 8th loop          CST-GFP12 mutant. Co-transfected with an EPO vector into CHO MAR-11 cells                     Partially reduced transport activity                                                                           EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0510]

  K272A                                 8th loop          CST-GFP12 mutant. Co-transfected with an EPO vector into CHO MAR-11 cells                     Complete inactivation of CST. Essential for CST transport activity                                             EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0510]

  K272G                                 8th loop          CST-GFP12 mutant. Co-transfected with an EPO vector into CHO MAR-11 cells                     Complete inactivation of CST. Essential for CST transport activity                                             EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0510]

  K272H                                 8th loop          CST-GFP12 mutant. Co-transfected with an EPO vector into CHO MAR-11 cells                     Complete inactivation of CST. Essential for CST transport activity                                             EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   Changed to His as His is in hGDP-fucose transporter. [@bb0510]

  Deletion of last 4 amino acids IIGV   C-terminal tail                                                                                                 Eliminated the export signals and prevented ER-to-Golgi translocation                                                                                            [@bb0400]

  TMD 2 & 3                             TMD 2\            hUGT-hCST chimera                                                                             Affects the efficiency of CST                                                                                                                                    [@bb0505]
                                        TMD 3                                                                                                                                                                                                                                                                            

  TMD 7                                 TMD 7             hUGT-hCST chimera                                                                             Required for substrate specificity                                                                                                                               [@bb0505]

  CST-GFP4\                             3rd loop          CST-GFP12 mutant. Co-transfected with an EPO vector into CHO MAR-11 cells                     Complete inactivation of CST                                                                                   EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0260; @bb0510]
  (GFP loop interruption)                                                                                                                                                                                                                                                                                                

  CST-GFP8\                             7th loop          CST-GFP12 mutant. Co-transfected with an EPO vector into CHO MAR-11 cells                     Complete inactivation of CST                                                                                   EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0260; @bb0510]
  (GFP loop interruption)                                                                                                                                                                                                                                                                                                

  CST-GFP10\                            8th loop          CST-GFP12 mutant. Co-transfected with an EPO vector into CHO MAR-11 cells                     Partial inactivation of CST                                                                                    EPO/IEF assay [a](#tf0005){ref-type="table-fn"}   [@bb0260; @bb0510]
  (GFP loop interruption)                                                                                                                                                                                                                                                                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EPO/IEF assay: Recombinant human erythropoietin/isoelectric focusing assay.
